Investigating Galectin-3 Levels During Respiratory Weaning
Prognostic Value of Galectin-3 for Success of Respiratory Weaning
Asklepios Neurological Clinic Bad Salzhausen · NCT05054556
This study is testing if measuring a protein called galectin-3 in patients on mechanical ventilation can help understand lung injury and improve how we manage their recovery when they are taken off the ventilator.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 150 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Asklepios Neurological Clinic Bad Salzhausen (other) |
| Locations | 2 sites (Bad König and 1 other locations) |
| Trial ID | NCT05054556 on ClinicalTrials.gov |
What this trial studies
This observational study aims to explore the correlation between galectin-3 levels and clinical parameters during the process of respiratory weaning from mechanical ventilation. Galectin-3 is a biomarker associated with fibrotic activity in the lungs, and its expression may indicate lung injury caused by mechanical ventilation. Patients undergoing invasive ventilation will have their serum galectin-3 levels measured upon admission, and these levels will be analyzed in relation to weaning outcomes. The study seeks to enhance understanding of lung injury mechanisms and improve patient management during respiratory support.
Who should consider this trial
Good fit: Ideal candidates for this study are patients who are currently receiving mechanical ventilation and can provide written informed consent.
Not a fit: Patients with a history of pulmonary disease or those with a left ventricular ejection fraction less than 45% may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide insights into the role of galectin-3 as a biomarker for lung injury, potentially leading to improved strategies for weaning patients from mechanical ventilation.
How similar studies have performed: While the role of galectin-3 in various conditions has been studied, this specific approach to correlate galectin-3 levels with respiratory weaning parameters is novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * written informed consent * mechanical ventilation Exclusion Criteria: * history of pulmonary disease * left ventricular ejection fraction\<45% * missing declaration of consent
Where this trial is running
Bad König and 1 other locations
- Asklepios Schlossberg Klinik Bad König — Bad König, Germany (RECRUITING)
- Neurologische Klinik Bad Salzhausen — Nidda, Germany (RECRUITING)
Study contacts
- Study coordinator: Dirk Bandorski, MD
- Email: d.bandorski@asklepios.com
- Phone: +496043804212
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Galectin-3 During Respiratory Weaning